According to the ETF Finder at ETF Channel, MRK makes up 8.70% of the Health Care Select Sector SPDR Fund ETF ( AMEX: XLV )which is trading higher by about 0.4% on the day Friday.

FORBES: Connect

The decision to get out of the primary care market is a major reason Bristol signed up Merck (nyse: MRK - news - people ) as a partner for muraglitazar, a diabetes drug that also treats heart disease.

FORBES: The 'Buy' Case For Bristol-Myers

Marketocracy's gurus showed exceptional bravery in their fourth-largest buy last week, scooping up shares of Merck (nyse: MRK - news - people ), which announced on Thursday that it was pulling its painkiller Vioxx off of the market due to safety concerns.

FORBES: Gurus Take Profits, Buy Up Battered Stocks

Pfizer 's (nyse: PFE - news - people ) Bextra, which increased the risk of heart attack and stroke in patients undergoing open heart surgery, and Arcoxia, Merck's (nyse: MRK - news - people ) still experimental follow-up to Vioxx, are the focus of a great deal of concern.

FORBES: Can Vioxx Rivals Take The Pressure?

Merck ( MRK - news - people ), which are just bulking up.

FORBES: Companies, People, Ideas

But this time the FDA put together a particularly tough crowd of more than 30 doctors, who are trying to figure out why it took so long to turn up dangerous heart side effects for Merck's (nyse: MRK - news - people ) Vioxx--and whether Pfizer's (nyse: PFE - news - people ) similar drugs, Celebrex and Bextra, should stay on the market.

FORBES: Pfizer And Merck Face The Jury

For years before Vioxx was yanked from the market in late 2004, Merck (nyse: MRK - news - people ) poured millions of dollars into testing a follow-up pill called Arcoxia.

FORBES: Vioxx, The Sequel

This is not a get-out-of-jail-free card for Merck (nyse: MRK - news - people ), which is still facing a flood of lawsuits stirred up by the Vioxx recall.

FORBES: Pfizer Wins